Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal DebtTotal LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Cytosorbents (CTSO) Total Liabilities (2016 - 2025)

Cytosorbents' Total Liabilities history spans 15 years, with the latest figure at $38.3 million for Q4 2025.

  • Quarterly results put Total Liabilities at $38.3 million for Q4 2025, up 5.55% from a year ago — trailing twelve months through Dec 2025 was $38.3 million (up 5.55% YoY), and the annual figure for FY2025 was $38.3 million, up 5.55%.
  • Total Liabilities for Q4 2025 was $38.3 million at Cytosorbents, up from $36.7 million in the prior quarter.
  • In the past five years, Total Liabilities ranged from a high of $38.3 million in Q4 2025 to a low of $10.2 million in Q1 2021.
  • The 5-year median for Total Liabilities is $27.9 million (2022), against an average of $29.2 million.
  • The sharpest move saw Total Liabilities tumbled 55.4% in 2021, then skyrocketed 172.44% in 2022.
  • Year by year, Total Liabilities stood at $26.9 million in 2021, then rose by 3.4% to $27.9 million in 2022, then increased by 5.81% to $29.5 million in 2023, then rose by 23.04% to $36.3 million in 2024, then grew by 5.55% to $38.3 million in 2025.
  • According to Business Quant data, Total Liabilities over the past three periods came in at $38.3 million, $36.7 million, and $36.4 million for Q4 2025, Q3 2025, and Q2 2025 respectively.